Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
JANX · Why this verdict
Why Janux Therapeutics (JANX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality metrics sit well below the minimum bar, with free cash flow burning at roughly 393% of revenue, no discernible competitive moat, and a weak Piotroski F-score of 2 out of 9. Quality breakdown | Free cash flow burn as a percentage of revenue should narrow meaningfully, and the Piotroski F-score should climb off its current low if the underlying business is stabilizing. | →Stable |
| CounterThe company has still beaten earnings estimates in three of the last four quarters with a positive average surprise, suggesting operational execution is better than the raw quality metrics imply. | ||
The stated risk/reward skews strongly favorable, with upside to the price target near 115% against roughly 7% downside to the stop-loss level, producing an asymmetry ratio of about 7.7. Targets | The favorable risk/reward should persist or widen if the shares continue closing the gap to the analyst target without downside accelerating. | →Stable |
| CounterThe position is still capped at an avoid-level size, and elevated short interest of 16% suggests other market participants see meaningful downside risk that the stated asymmetry does not fully capture. | ||
The company has beaten earnings estimates in three of its last four quarters, a pattern the data characterizes as strong earnings performance with a positive average surprise. Catalyst breakdown | Continued beats with a positive average surprise over the next several quarters would reinforce execution strength despite weak headline quality metrics. | →Stable |
| CounterThe one miss in the trailing four quarters shows the beat streak is not unbroken, and losses per share remain negative across all periods, meaning the company is still burning cash even when it beats estimates. | ||
Momentum readings describe a death-cross setup with the stock below its 200-day moving average and a 30-day slope of about -7.6%, characterized in the data as a confirmed downtrend, even though RSI at 72 shows an overbought bounce within that decline. Momentum breakdown | A recovery back above the 200-day moving average with a stabilizing or positive moving-average slope would indicate the downtrend is reversing. | →Stable |
| CounterThe death-cross warning is already flagged as recovering, and MACD is improving, suggesting the downtrend may be in its later stages rather than accelerating. | ||
Insider activity skews bearish, with net insider selling over the past 90 days and no offsetting buys, coinciding with short interest at 16% that the data describes as justified. Insider | A shift toward net insider buying, or a material decline in short interest, would indicate the bearish positioning is unwinding. | →Stable |
| CounterThe trailing sell count is only two transactions with no disclosed dollar value, a small signal that may not represent a strong conviction bearish view from insiders. | ||
Quality metrics sit well below the minimum bar, with free cash flow burning at roughly 393% of revenue, no discernible competitive moat, and a weak Piotroski F-score of 2 out of 9.
→StableQuality breakdown
- Expectation
- Free cash flow burn as a percentage of revenue should narrow meaningfully, and the Piotroski F-score should climb off its current low if the underlying business is stabilizing.
CounterThe company has still beaten earnings estimates in three of the last four quarters with a positive average surprise, suggesting operational execution is better than the raw quality metrics imply.
The stated risk/reward skews strongly favorable, with upside to the price target near 115% against roughly 7% downside to the stop-loss level, producing an asymmetry ratio of about 7.7.
→StableTargets
- Expectation
- The favorable risk/reward should persist or widen if the shares continue closing the gap to the analyst target without downside accelerating.
CounterThe position is still capped at an avoid-level size, and elevated short interest of 16% suggests other market participants see meaningful downside risk that the stated asymmetry does not fully capture.
The company has beaten earnings estimates in three of its last four quarters, a pattern the data characterizes as strong earnings performance with a positive average surprise.
→StableCatalyst breakdown
- Expectation
- Continued beats with a positive average surprise over the next several quarters would reinforce execution strength despite weak headline quality metrics.
CounterThe one miss in the trailing four quarters shows the beat streak is not unbroken, and losses per share remain negative across all periods, meaning the company is still burning cash even when it beats estimates.
Momentum readings describe a death-cross setup with the stock below its 200-day moving average and a 30-day slope of about -7.6%, characterized in the data as a confirmed downtrend, even though RSI at 72 shows an overbought bounce within that decline.
→StableMomentum breakdown
- Expectation
- A recovery back above the 200-day moving average with a stabilizing or positive moving-average slope would indicate the downtrend is reversing.
CounterThe death-cross warning is already flagged as recovering, and MACD is improving, suggesting the downtrend may be in its later stages rather than accelerating.
Insider activity skews bearish, with net insider selling over the past 90 days and no offsetting buys, coinciding with short interest at 16% that the data describes as justified.
→StableInsider
- Expectation
- A shift toward net insider buying, or a material decline in short interest, would indicate the bearish positioning is unwinding.
CounterThe trailing sell count is only two transactions with no disclosed dollar value, a small signal that may not represent a strong conviction bearish view from insiders.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Janux Therapeutics shows weak underlying quality metrics and cash burn, but a beaten-down price has produced a stated risk/reward skewed heavily toward upside, backed by a recent streak of earnings beats, even as momentum remains in a confirmed downtrend and insiders lean bearish.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -393% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 2.8 |
- ▸Overbought bear rally (RSI 78)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -7.5%/30d — confirmed downtrend
Sentiment
8.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.7 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 123%
Insider
6.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 7.0 |
- ▸Insider selling (low materiality) — $85,822 (0.009% of mkt cap)
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.5 |
| quality rank | 7.6 |
| growth rank | 5.0 |
Technical
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.9 |
| days to cover | 1.9 |
| volatility | 1.1 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 1.6 |
| debt equity | 9.9 |
- ▸High short interest justified: 16%
- ▸High IV: 95%
- ▸Above max pain $2
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.3>=5.5
- ASYMMETRY:6.7>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- DEATH_CROSS:momentum=6.3>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
6.73
Upside
+100.9%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 78
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Drawdown -53% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 8.1, and Catalyst at 6.7; the weakest are Technical at 1.5, Quality at 1.8, and Risk (lower is worse) at 3.7. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 6.73 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burn And Weak Quality
Trip ifFree cash flow-to-revenue ratio rises above -100% from the current -393%.
- P2Favorable Risk Reward Skew
Trip ifThe risk/reward ratio compresses below 1.5x from the current 7.69x.
- P3Recent Earnings Beat Streak
Trip ifEPS surprise falls below 0% (a miss) for 2 consecutive quarters.
- P4Confirmed Downtrend Momentum
Trip ifThe 200-day moving-average slope rises above 0% per 30 days, turning positive from the current -7.6%.
- P5Bearish Insider Positioning
Trip ifShort interest falls below 10% of float from the current 16%.